International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 1, pp: (311-320), Month: April - September 2017, Available at: www.researchpublish.com

Overview of Radiotherapy and Clinical Staging for Patients Suffering Rectal Malignant Tumor

[1]Abdulaziz Faisal Khyat, [2]Turki Tawfik Alshaikh, [3]Mahmoud Abdulghafur Sait,
[4]Ahmed Faisal Basalam, [5]Yazeed Abdullah Aldousari,
[6]Abdulrahman Mohammed Hamza, [7]Mohmad Ahmed Hamodah

Abstract: **This review study was aimed to overview the rectal cancer or colorectal cancer in meanwhile we intended to emphasize the staging methods of rectal carcinoma according to different evidence, also aimed to review the radiation therapy for rectal cancer, and comparing the evidence in that manner. We conducted a detailed search through medical electronic databases' Medline/PubMed and Embase, searching studies discussing rectal cancer staging, radiotherapy, and risk factors associated with rectal cancer, published up to May, 2017. English language restriction was applied to the search and we included those studies with human subjects only. Rectal cancer staging defines neighborhood as well as distant extent of disease. Postsurgical pathologic hosting offers info on prognosis and also could show the demand for additional treatment. Pretreatment staging establishes management. Exact analysis of neighborhood T, N, as well as M classifications is most importantly crucial for identifying the best stage-specific therapy. Present assessment methods consist of physical examination, plain radiographs, EUS, MRI, accurate for staging. The trials have repetitively revealed that RT, whether alone or with radiation treatment, ought to be provided prior to surgical treatment to have the best effectiveness as well as the very least toxicity. It is also a belief that systemic therapy, being the weakest part of the treatment, need to be given before and not after the surgery in order to have biggest efficacy. Development of the local primary ought to after that not happen throughout the systemic therapy, presently needing a duration of 5-6 mo. The discovery that the short-course schedule results in significant down-staging, is bearable as well as permits complete radiation treatment beginning soon after the RT.**

Keywords: **Rectal Malignant Tumor, rectal cancer or colorectal cancer.**

1. INTRODUCTION

Rectal cancers are the second most common (28%) cancers in large intestinal tract after proximal colon cancers cells (42%) [(1)]. Therefore, rectal cancers have constantly been taken into consideration as a part of Colorectal cancers (CRCs) in relevant epidemiological researches. CRC, as one of the significant public health troubles, is the 3rd most usual cancer in males and also the 2nd in women in the world with a lifetime likelihood of 4.7-5% [(2)]. Initiatives to decrease anal cancer loco-regional reappearance prices by better hosting, boosted surgery and also incorporation of radiotherapy are the most likely factors for the currently slightly far better 5-year survival rates in anal cancer. The neighborhood reoccurrence prices have likewise decreased from 30%-40% a few decades ago down to 5%-10% and even lower in some recent studies, and this has actually affected survival in certain population-based studies. Survival still differs thoroughly in between countries, and also distinctions in treatment traditions are most likely a significant reason for this [(3)].

Although geographical occurrence of CRC differs worldwide, its pattern is comparable among women as well as guys. Presently, CRCs seem to be much more typical in developed regions of the globe. The highest possible approximated prices is in Australia/New Zealand (44.8 as well as 32.2 per 100,000 in ladies and also males respectively), and also the lowest in Western Africa (4.5 and 3.8 per 100,000) [(2)]. According to a recent information from the United States, roughly 136,830 new cases of CRC are detected every year, consisting of 40,000 anal cancers cells [(4)]. Inaccuracy of electronic anal exam adhering to chemoradiotherapy (CRT) within in the workplace, center or at the time of procedure has been well

demonstrated, with an unfavorable anticipating worth of between 21% to 24% [5,6,7]. Combined with professional examination, endoscopic analysis with biopsy has been shown to have an incorrect adverse rate of 69%, though its merit perhaps being located to be a 0% incorrect favorable price [8]. Generally, the pretreatment neighborhood hosting for anal cancer consists of digital rectal assessment, proctoscopy, transrectal ultrasonography (TRUS), pelvic computed tomography (CT), as well as magnetic resonance imaging (MRI). Much more lately, positron emission tomography has actually also been thought about [9,10].

This review study was aimed to overview the rectal cancer or colorectal cancer in meanwhile we intended to emphasize the staging methods of rectal carcinoma according to different evidence, also aimed to review the radiation therapy for rectal cancer, and comparing the evidence in that manner.

2. METHODOLOGY

We conducted a detailed search through medical electronic databases' Medline/PubMed and Embase, searching studies discussing rectal cancer staging, radiotherapy, and risk factors associated with rectal cancer, published up to May, 2017. English language restriction was applied to the search and we included those studies with human subjects only.

3. RESULTS

- **Etiological Factors associated with rectal cancer:**

A multitude of reviews and research studies have actually taken into consideration risk factors in CRCs normally, nevertheless, a minimal number of them have aimed to different environmental and also hereditary factors that can influence the chance of colon and also anal cancers cells [11,12].

Studies have verified that a family history of intestines cancer appears to affect risk for colon cancer more strongly than risk for anal cancer [11]. Prevalence of K-ras mutations and anomaly patterns in the p53 gene in rectal cancers cells are additionally different from those seen in colon cancers cells [13].

Age and also gender are very important risk factors influencing both colon and also rectal cancers cells [11]. A statistically substantial raised risk for colon cancer has been reported with raised elevation. For the Body Mass Index (BMI), there is a various effect on CRCs in between ladies and also men. A methodical evaluation has reported that each 5 kg/m2 rise in BMI is associated with a 24% as well as 9% raised occurrence of CRCs in men and women, respectively [14]. Moreover, there is a significant enhanced risk in the highest possible category of BMI among the females for rectal cancer [11].

Environmental factors such as diet regimen and exercise could additionally affect the risk. Contradictory outcomes have been released on the role of calcium on anal cancers. Wei et alia [11] showed that patients with rectal cancers had the tendency to have slightly higher folate and also slightly reduced calcium intake, whereas Wu et al. [15] located a significant organization between calcium and also cancers cells occurring in the distal colon. It has actually additionally been shown that diet plans with greater milk and dairy item are associated with a substantial decrease in the risk of colon cancer, not affecting the risk of rectal cancer [16]. An inverted association has actually been revealed in between magnesium consumption and the risk of both colon and also anus cancers cells in females [17]. Exercise has actually been located to be a lot more highly associated with colon cancer than rectal cancer. A slightly stronger organization is reported in between smoking and also anal cancer in contrast to colon cancer [11,17]. A background of radiation therapy for prostate cancer is an additional risk factor of rectal cancer [13]. According to a meta-analysis, risk of colon and anal cancers cells among patients with diabetes mellitus was approximately 38% and also 20% higher than non-diabetic patients, specifically [14,17].

- **Staging methods of Rectal cancer:**

Rectal cancer staging has actually had a long evolution. In 1926, Lockhart-Mummery [18,19] proposed a staging system for anal cancer. In this system, the deepness of invasion and lymph node positivity identified in samplings gotten rid of at surgical treatment were determined as essential prognostic factors. In 1932, Dukes [20] summed up present point of view, stating that in its earliest stages, anal cancer begins as an epithelial expansion rising from the surface and that carcinoma develops from a pre-existing adenoma. The cancer spreads via the digestive tract wall to the lymphatics. Cases where the cancer is restricted to the wall surface of the anus were designated A. Those in which the cancer has spread by straight connection to the extrarectal tissue were marked B. Cases in which metastases are present in the local lymph nodes were called C (**Figure1)** (20). A more advanced pathologic phase was related to a worse prognosis.



Figure 1: Rectal cancer staging system proposed by Dukes in 1932.

Suitable diagnosis as well as staging are fundamental as pertains to choose of treatment. Tumours with distal expansion to 15 cm or much less from the anal margin (as determined by stiff sigmoidoscopy) are classified as anal, and also much more proximal tumours as colonic. Others, e.g., in Japan [21], prefer to separate colon and also rectal cancers at the peritoneal representation, or concerning 9-12 centimeters from the anal verge. Given that the localization of the tumor in connection with other organs and also frameworks and hence, the range from the rectal brink, is necessary for result as well as treatment, cancers between 10 and also 15 cm are, in this author's opinion, finest discussed as rectal cancers given that radiotherapy (RT) is a vital part of therapy, even if this is much less usual compared to for lower rectal cancers cells (0-10 centimeters) [22]. Lateral lymph node involvement is, however, uncommon in tumors above the peritoneal representation [23].

Rectal MRI is recommended for hosting in order to pick preoperative treatment and extent of surgery, although endoscopic ultrasonography could be used for the earliest tumours [24,25]. If MRI and also ultrasound are combined, a study asserted that accuracy was enhanced [26]. The TNM staging system need to be utilized. At present, the current variation 7 from 2010 is liked by most, also if it shows significant interobserver variants in defining phases II and also III [27]. There is a need for further subclassification of clinical phase T3 (cT3) (Table 1) in order to individualize treatment, i.e., to make a decision whether surgery alone is ideal or whether preoperative RT alone or with chemotherapy (CRT) should be advised [27].

TABLE 1: Tumor node metastasis-7 classification (2010) with sub-classification of stage T3

TNM	Extension to
Tis	Carcinoma in situ: intraepithelial or invasion of lamina propria
T1	Submucosa
T2	Muscularis propria
T3	Subserosa/perirectal tissue
T3a[1]	Less than 1 mm
T3b	1-5 mm
T3c	5-15 mm
T3d	15+ mm
T4	Perforation into visceral peritoneum (a) or invasion to other organs (b)
N1	1-3 regional nodes involved
N1a	1 lymph node
N1b	2-3 lymph nodes
N1c	Small deposits in the fat
N2	4 or more regional nodes involved
N2a	4-6 lymph nodes
N2b	7 or more lymph nodes
M1	Distant metastases
M1a	1 distant organ or set of lymph nodes
M1b	More than 1 organ or to the peritoneum

[1]This subclassification is based upon an evaluation using magnetic resonance imaging prior to treatment decision is clinically valuable, and recommended in this review. It can be used also in the histopathological classification but is not validated and not incorporated in TNM version 7. TNM: Tumor node metastasis.

A precise hosting system can be valuable in selecting the best therapeutic alternative for patients dealing with cancers. It could additionally assist medical professional to assess outcomes of their management. The TNM (Tumor, Node as well as Metastasis) hosting system for intestines cancers offered by the American Joint Committee on Cancer (AJCC) [(28)] is currently made use of worldwide. One of the most recent 7th version (2010) specifies a revised staging system. Class of T4, N1, N2, and also M1 in addition to substaging of stage II is amongst the modifications in the new version.

- **Duties of Endorectal Ultrasound and also MRI in staging of Rectal cancer:**

Endorectal ultrasound (EUS) has gained popularity over the last ten years as it has been shown to accurately present anal tumors prior to any kind of therapy [(29)]. This precision has not been replicated article radiotherapy. Maretto et alia [(30)] demonstrated a 77% sensitivity in EUS T phase assessment following CRT, though just a 33% uniqueness. Nevertheless, EUS had an 81% unfavorable anticipating value for examining participation of lymph nodes, compared with only a 65% adverse predictive value for MRI in lymph node status in the very same research study [(30)]. Various other studies supported these findings showing 63% and 54% precision in analyzing T stage of rectal tumours (consisting of T0), with a 77% as well as 75% unfavorable anticipating worth for lymph node involvement specifically [(31,32)]. The poor dependability of EUS as a diagnostic tool following CRT has been echoed elsewhere in the literary works, and as a result has actually not been formerly advocated as a security device [(33)].

Orrom as well as associates [(34)] defined a five-layer design of the rectal wall as seen by ultrasound with 3 echogenic (white lines) and also 2 echo-poor (dark lines) as shown in (**Figure 2**). The ultrasonic staging system is based upon deepness of intrusion and lymph node positivity. An example of a uT3 sore is displayed in (**Figure 3**).



Figure 2: Five-layer model for the interpretation of endorectal ultrasound.



Figure 3: Endorectal ultrasound of a uT3 rectal cancer. The scalloped pattern of the outer tumor edge is consistent with penetration of the muscularis mucosa (large arrow). Note the five layers of the normal rectal wall (small arrow)

EUS is useful because the exam can be done as an office procedure with very little prep work. There are a number of disadvantages: During the exam, the transducer needs to be held at a best angle to the tumor, which might not be possible to achieve, particularly for upper rectal or stenotic tumors [35]; EUS does not completely examine the mesorectum or the mesorectal envelope; the capability of EUS to find lymph nodes is only fair; as well as analysis of EUS pictures depends on the experience of the driver.

The accuracy of EUS in anticipating pathologic stage is defined best by large research studies. In 2004, Kauer [36] described 458 patients with rectal cancer in which the EUS phase was compared to the pathologic phase. The general rate for properly categorized patients was 69% with respect to the T group and also 68% relative to the N category. The T3 classification tumors were the most properly recognized (86%), and the T4 tumors were the least precisely determined (36%). Tumor overstaging (19%) was a lot more frequent that understaging (12%). A high interobserver irregularity was

noted. For pathologic phase T1 tumors, the 10-MHz check was nearly 2 times extra accurate that the 7.5-MHz check (71% versus 36%). The authors concluded that the accuracy of EUS staging of rectal cancer depends on the T-category. They likewise discovered that a high-resolution scanner as well as a knowledgeable examiner provide the very best results, specifically for early cancer [36].

In 2005, Knaebel et al [37] explained 424 patients undertaking EUS for rectal cancer that went through surgery. They contrasted the preoperative EUS findings with postoperative pathology as well as located a T classification precision of 81% and an N classification precision of 76%. In a second collection of an added 332 patients with rectal tumors (including adenomas), the authors discovered that endosonography was most accurate when done by seasoned people which EUS is inaccurate when used for hosting in patients who have undertaken chemoradiation.

In 2005, Harewood [38] did a MEDLINE look for all released quotes of EUS accuracy in staging anal cancer between 1985 as well as 2003. Two-hundred two abstracts were reviewed. The EUS findings of 4118 topics were reported with an overall mean T-staging accuracy of 85% and also N-staging accuracy of 75%. There was a paucity of smaller research studies expressing reduced EUS precision prices. The accuracy rates both of T-staging and N-staging declined gradually with the lowest rates reported in more recent literature. The writer wrapped up that the performance of EUS in staging anal cancer could be overestimated in the literature as a result of publication predisposition and that this filled with air quote of the capability of EUS may lead to unrealistic assumptions for this innovation.

In 2006, Ptok et al [39] researched the usefulness as well as accuracy of EUS in the pretreatment staging of anal cancer. In general, 13,610 patients with rectal cancer were registered in the study. 5 thousand fifty-six topics (37%) went through EUS. In 3501 patients, EUS findings (uT-stage) would certainly be compared with the conclusive histologic examination (pT-stage). EUS accuracy in all T groups was 66%. The highest level of sensitivity was attained in the T3 group (75%); for T4, t2, and t1, it was 59%, 59%, and 31%, respectively. In this large study, effective completion of EUS as well as analysis precision were not like that reported in the earlier researches.

- **Treatment of rectal cancer:**

The therapy for rectal cancer is intricate and relies on the results of pathologic evaluation that occurs adhering to medical inspection of the damaged location as well as determination of cancer spread [40]. The first therapy effort is medical resection, preferably. Cancers regarded to be in phase 0 or stage I are most likely to get no preliminary extra medical treatment beyond surgery. Patients in stages IIA and IIB might obtain adjuvant chemotherapy or be observed very closely adhering to surgical resection. Patients with any kind of sort of stage III disease must be used adjuvant chemotherapy following surgery. All patients are consequently monitored over the following 5 years following these preliminary treatments to study for abnormalities recommending the possible return of cancer. Patients with stage IV disease have shown metastases as well as for that reason need a factor to consider of more facility therapy options based on the place of the metastases and also their degree of respectability [40]. They may at first receive neoadjuvant chemotherapy adhered to by medical resection of the colon as well as metastases, followed by adjuvant radiation treatment as well as resection of metastatic disease. Those patients in which the primary tumor is initially unrespectable may be supplied palliative treatment due to the advanced nature of their disease [40].

- **Radiotherapy (RT) for rectal cancer:**

Advantages that have actually typically been connected with preoperative RT, in contrast to RT given postoperatively, relate to both tumor reaction as well as preservation of normal cells [41,42,43]. Of all, minimizing tumor quantity could help with resection and raise the possibility of a sphincter-sparing procedure [41,42]. Second, irradiating cells that is surgery-naïve as well as thus better oxygenated could result in increased level of sensitivity to RT. Tumor cells are considerably a lot more sensitive to an equal dose of RT in the presence of oxygen instead of hypoxic conditions [43]. Third, preoperative RT can avoid the occurrence of RT-induced injury to the little bowel trapped in the pelvis by postsurgical bonds [41]. The anastomosis remains untouched by the results of RT because irradiated cells is resected. Preoperative RT that includes frameworks that will certainly be resected rises the probability that an anastomosis with a healthy colon can be done. However, one downside of using preoperative RT is the opportunity of over-treating early-stage tumors that do not require adjuvant RT. Recent renovations in preoperative hosting techniques have actually enabled even more exact hosting, yet the risk of over-staging the disease has not been removed [44].

In the trial [45,46] considerably less regional recurrences (13% vs 22%, $P < 0.05$) was seen in the team of patients randomized to the short preoperative timetable than to an "maximized" postoperative timetable (high complete radiation

dosage, 60 Gy in 7-8 wk, just given to high risk teams, phases II + III). Consequently, several tests contrasting preoperative CRT with postoperative CRT were initiated. The only finished test [47] once more showed that preoperative treatment was a lot more efficient and also less toxic compared to postoperative. The preoperative treatment was additionally much less hazardous. No distinction in survival was identified. Supremacy of preoperative short-course RT over postoperative CRT was likewise received the MRC-CR07-trial; regional recurrences were much less frequently seen in the preoperatively irradiated team (5% vs 11%, $P < 0.01$) [48]. The majority of the globe has actually now approved that added (C)RT in anal cancer must be provided before, i.e., neo-adjuvant, rather than after surgery. An evaluation of data from the randomized studies additionally showed that preoperative RT is much more dose-efficient compared to postoperative RT [49].

Radiotherapy combined with chemotherapy:

Three randomized tests, two in the intermediate team [50,51] and also one in the in your area advanced, awful group [52] have provided a solution to the 3rd question. Neighborhood control was better in the combined treatment arm in all 3 studies, whereas a considerable survival gain was just seen in the trial consisting of in your area innovative cancers cells [52]. Whenever a patient with an in your area advanced, hideous anal cancer obtains preoperative therapy, CRT ought to be utilized unless the patient cannot tolerate this therapy. It should, nonetheless, be recognized that the gains from the chemotherapy enhancement are instead restricted and also featured a rather high rate with substantially raised acute toxicity.

The drug most thoroughly used to sensitize the RT has actually been 5-fluorouracil (5-FU), although oral capecitabine gives the very same potentiation of the impacts, as well as is easier [53]. Other oral fluoropyrimidines such as UFT [54,55] have also been discovered, yet have not yet been the topic of randomized tests. Combinations of 5-FU and various other cytotoxic drugs such as oxaliplatin and also irinotecan, as well as targeted medicines, have actually been thoroughly discovered during the past decade. Multiple phase II studies in so-called "locally innovative rectal cancer" have claimed premium outcomes [much more down-sizing, higher pathological full (pCR) rates] It is likely that these apparently favourable outcomes depend upon the inclusion of primarily early or intermediate cancers cells. Five large randomized tests have actually failed to show any exceptional arise from the enhancement of oxaliplatin [56,57,58]. When cetuximab was included in CRT with capecitabine and also neo-adjuvant chemotherapy with capecitabine-oxaliplatin in a randomized stage II research study, the primary endpoint, pCR price, was not raised, but extra radiological feedbacks (89% vs 72%, $P = 0.002$) and boosted OS (96% vs 81% at 3 years, $P = 0.04$) were seen in the KRAS wild-type populace ($n = 90$) [59].

4. CONCLUSION

Rectal cancer staging defines neighborhood as well as distant extent of disease. Postsurgical pathologic hosting offers info on prognosis and also could show the demand for additional treatment. Pretreatment staging establishes management. Exact analysis of neighborhood T, N, as well as M classifications is most importantly crucial for identifying the best stage-specific therapy. Present assessment methods consist of physical examination, plain radiographs, EUS, MRI, accurate for staging. The trials have repetitively revealed that RT, whether alone or with radiation treatment, ought to be provided prior to surgical treatment to have the best effectiveness as well as the very least toxicity. It is also a belief that systemic therapy, being the weakest part of the treatment, need to be given before and not after the surgery in order to have biggest efficacy. Development of the local primary ought to after that not happen throughout the systemic therapy, presently needing a duration of 5-6 mo. The discovery that the short-course schedule results in significant down-staging is bearable as well as permits complete radiation treatment beginning soon after the RT.

REFERENCES

[1] Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(2):104–17. doi: 10.3322/caac.21220.

[2] GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012: International Agency for research on Cancer. World Health Organization; 2014

[3] Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, Maxwell R, Nedrebø B, Påhlman L, Sjövall A, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol. 2013;52:919–932.

[4] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA. 2014;64(1):9–29. doi: 10.3322/caac.21208

[5] Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131–135; discussion 135-135.

[6] Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, Paty PB, Saltz L, Minsky BD, Weiser MR, et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol. 2005;23:3475–3479.

[7] Kahn H, Alexander A, Rakinic J, Nagle D, Fry R. Preoperative staging of irradiated rectal cancers using digital rectal examination, computed tomography, endorectal ultrasound, and magnetic resonance imaging does not accurately predict T0,N0 pathology. Dis Colon Rectum. 1997;40:140–144.

[8] Maretto I, Pomerri F, Pucciarelli S, Mescoli C, Belluco E, Burzi S, Rugge M, Muzzio PC, Nitti D. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2007;14:455–461.

[9] Kim NK, Kim MJ, Yun SH, Sohn SK, Min JS. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. Dis Colon Rectum 1999; 42:770–5.

[10] Herbst F. Pelvic radiological imaging: a surgeons perspective. Eur J Radiol 2003; 47:135–41

[11] Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. International journal of cancer Journal international du cancer 2004;108(3):433-42. PMCID: 2903217. doi: 10.1002/ijc.11540.

[12] Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010;138(6):2029-43 e10. PMCID: 2947820. doi: 10.1053/j.gastro.2010.01.057.

[13] Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Annals of Internal Medicine. 2012;156(10):703–9. doi: 10.7326/0003-4819-156-10-201205150-00006.

[14] Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi: 10.1016/S0140-6736(08)60269-X.

[15] Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. Journal of the National Cancer Institute. 2002;94(6):437–46.

[16] Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E. et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Annals of Oncology. 2012;23(1):37–45.

[17] Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA. 2005;293(1):86–9. doi: 10.1001/jama.293.1.86.

[18] Zinkin L D. A critical review of the classifications and staging of colorectal cancer. Dis Colon Rectum. 1983;26:37–43.

[19] Lockhart-Mummery J P. Two hundred cases of cancer of the rectum treated by perineal excision. Br J Surg. 1926–1927;14:110–124.

[20] Dukes C E. The classification of cancer of the rectum. J Pathol Bacteriol. 1932;35:323–332.

[21] Japanese Society for Cancer of the Colon and Rectum. In: Colorectal carcinoma. Japanese classification. 2th ed. Tokyo: Kanehara; 2009.

[22] Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2) Radiother Oncol. 2009;92:148–163.

[23] Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg. 2008;95:33–49.

[24] Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology. 2004;232:773–783.

[25] Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 2008;47:20–31.

[26] Swartling T, Kälebo P, Derwinger K, Gustavsson B, Kurlberg G. Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer. World J Gastroenterol. 2013;19:3263–3271.

[27] Quirke P, Cuvelier C, Ensari A, Glimelius B, Laurberg S, Ortiz H, Piard F, Punt CJ, Glenthoj A, Pennickx F, et al. Evidence-based medicine: the time has come to set standards for staging. J Pathol. 2010;221:357–360.

[28] Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York: Springer; 2010.

[29] Hünerbein M. Endorectal ultrasound in rectal cancer. Colorectal Dis. 2003;5:402–405.

[30] Maretto I, Pomerri F, Pucciarelli S, Mescoli C, Belluco E, Burzi S, Rugge M, Muzzio PC, Nitti D. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2007;14:455–461.

[31] Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. Am J Gastroenterol. 2004;99:109–112.

[32] Pastor C, Subtil JC, Sola J, Baixauli J, Beorlegui C, Arbea L, Aristu J, Hernandez-Lizoain JL. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? Dis Colon Rectum. 2011;54:1141–1146.

[33] Williamson PR, Hellinger MD, Larach SW, Ferrara A. Endorectal ultrasound of T3 and T4 rectal cancers after preoperative chemoradiation. Dis Colon Rectum. 1996;39:45–49.

[34] Orrom W J, Wong W D, Rothenberger D A, Jensen L L, Goldberg S M. Endorectal ultrasound in the preoperative staging of rectal tumors. Dis Colon Rectum. 1990;33:654–659.

[35] Nesbakken A, Løvig T, Lunde O C, Nygaard K. Staging of rectal carcinoma with transrectal ultrasonography. Scand J Surg. 2003;92:125–129.

[36] Kauer W KH, Prantl L, Dittler H J, Siewart J R. The value of endosonographic rectal carcinoma staging in routine diagnostics. Surg Endosc. 2004;18:1075–1078.

[37] Knaebel H-P, Koch M, Feise T, Benner A, Kienle P. Diagnostics of rectal cancer: endorectal ultrasound. Recent Results Cancer Res. 2005;165:46–57.

[38] Harewood G C. Assessment of publication bias in the reporting EUS performance in staging rectal cancer. Am J Gastroenterol. 2005;100:808–816.

[39] Ptok H, Marusch F, Meyer F, et al. Feasibility and accuracy of TRUS in the pre-treatment staging for rectal carcinoma in general practice. Eur J Surg Oncol. 2006;32:420–425.

[40] National Comprehensive Cancer Network. Colon Cancer. Practice Guidelines in Oncology- v.1.2008.

[41] Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740.

[42] Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PP. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys. 1998;42:51–57.

[43] Kachnic LA. Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol. 2006;33(6 Suppl 11):S64–S69.

[44] Madoff RD. Chemoradiotherapy for rectal cancer--when, why, and how? N Engl J Med. 2004; 351:1790–1792.

[45] Påhlman L, Glimelius B, Graffman S. Pre- versus postoperative radiotherapy in rectal carcinoma: an interim report from a randomized multicentre trial. Br J Surg. 1985;72:961–966.

[46] Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg. 1990;211:187–195.

[47] Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740.

[48] Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–820.

[49] Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys. 1997;37:281–287.

[50] Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625.

[51] Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123.

[52] Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26:3687–3694.

[53] Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579–588.

[54] Vestermark LW, Jensen HA, Pfeiffer P. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Acta Oncol. 2012;51:311–317.

[55] Ishihara S, Hayama T, Yamada H, Nozawa K, Matsuda K, Watanabe T. Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer. Hepatogastroenterology. 2011;58:756–762.

[56] Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679–687.

[57] Schmoll J, Haustermans K, Jay Price T, Nordlinger B, Hofheinz R, Daisne J-F, Janssens J, Brenner B, Schmidt P, Reinel H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. J Clin Oncol. 2013;31:Abstr 3531.

[58] Roh MS, Yothers GA, O'Connell MJ, Beart RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011;29:Abstr 3503.

[59] Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) J Clin Oncol. 2012;30:1620–1627.